Cargando…

Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine

The efficacy of hydroxychloroquine (HCQ) therapy, a previous candidate drug for coronavirus disease 2019 (COVID-19), was denied in the global guideline. The risk of severe cardiac events associated with HCQ was inconsistent in previous reports. In the present case series, we show the tolerability of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Tomohiro, Okamoto, Masaki, Matsuo, Norikazu, Naitou-Nishida, Yoshiko, Nouno, Takashi, Kojima, Takashi, Nishii, Yuuya, Uchiyashiki, Yoshihiro, Takeoka, Hiroaki, Nagasaki, Yoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057902/
https://www.ncbi.nlm.nih.gov/pubmed/36984543
http://dx.doi.org/10.3390/medicina59030541
_version_ 1785016483116482560
author Tanaka, Tomohiro
Okamoto, Masaki
Matsuo, Norikazu
Naitou-Nishida, Yoshiko
Nouno, Takashi
Kojima, Takashi
Nishii, Yuuya
Uchiyashiki, Yoshihiro
Takeoka, Hiroaki
Nagasaki, Yoji
author_facet Tanaka, Tomohiro
Okamoto, Masaki
Matsuo, Norikazu
Naitou-Nishida, Yoshiko
Nouno, Takashi
Kojima, Takashi
Nishii, Yuuya
Uchiyashiki, Yoshihiro
Takeoka, Hiroaki
Nagasaki, Yoji
author_sort Tanaka, Tomohiro
collection PubMed
description The efficacy of hydroxychloroquine (HCQ) therapy, a previous candidate drug for coronavirus disease 2019 (COVID-19), was denied in the global guideline. The risk of severe cardiac events associated with HCQ was inconsistent in previous reports. In the present case series, we show the tolerability of HCQ therapy in patients treated in our hospital, and discuss the advantages and disadvantages of HCQ therapy for patients with COVID-19. A representative case was a 66-year-old woman who had become infected with severe acute respiratory syndrome coronavirus 2 and was diagnosed as having COVID-19 pneumonia via polymerase chain reaction. She was refractory to treatment with levofloxacin, lopinavir, and ritonavir, while her condition improved after beginning HCQ therapy without severe side effects. We show the tolerability of HCQ therapy for 27 patients treated in our hospital. In total, 21 adverse events occurred in 20 (74%) patients, namely, diarrhea in 11 (41%) patients, and elevated levels of both aspartate aminotransferase and alanine transaminase in 10 (37%) patients. All seven grade ≥ 4 adverse events were associated with the deterioration in COVID-19 status. No patients discontinued HCQ treatment because of HCQ-related adverse events. Two patients (7%) died of COVID-19 pneumonia. In conclusion, HCQ therapy that had been performed for COVID-19 was well-tolerated in our case series.
format Online
Article
Text
id pubmed-10057902
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100579022023-03-30 Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine Tanaka, Tomohiro Okamoto, Masaki Matsuo, Norikazu Naitou-Nishida, Yoshiko Nouno, Takashi Kojima, Takashi Nishii, Yuuya Uchiyashiki, Yoshihiro Takeoka, Hiroaki Nagasaki, Yoji Medicina (Kaunas) Case Report The efficacy of hydroxychloroquine (HCQ) therapy, a previous candidate drug for coronavirus disease 2019 (COVID-19), was denied in the global guideline. The risk of severe cardiac events associated with HCQ was inconsistent in previous reports. In the present case series, we show the tolerability of HCQ therapy in patients treated in our hospital, and discuss the advantages and disadvantages of HCQ therapy for patients with COVID-19. A representative case was a 66-year-old woman who had become infected with severe acute respiratory syndrome coronavirus 2 and was diagnosed as having COVID-19 pneumonia via polymerase chain reaction. She was refractory to treatment with levofloxacin, lopinavir, and ritonavir, while her condition improved after beginning HCQ therapy without severe side effects. We show the tolerability of HCQ therapy for 27 patients treated in our hospital. In total, 21 adverse events occurred in 20 (74%) patients, namely, diarrhea in 11 (41%) patients, and elevated levels of both aspartate aminotransferase and alanine transaminase in 10 (37%) patients. All seven grade ≥ 4 adverse events were associated with the deterioration in COVID-19 status. No patients discontinued HCQ treatment because of HCQ-related adverse events. Two patients (7%) died of COVID-19 pneumonia. In conclusion, HCQ therapy that had been performed for COVID-19 was well-tolerated in our case series. MDPI 2023-03-10 /pmc/articles/PMC10057902/ /pubmed/36984543 http://dx.doi.org/10.3390/medicina59030541 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Tanaka, Tomohiro
Okamoto, Masaki
Matsuo, Norikazu
Naitou-Nishida, Yoshiko
Nouno, Takashi
Kojima, Takashi
Nishii, Yuuya
Uchiyashiki, Yoshihiro
Takeoka, Hiroaki
Nagasaki, Yoji
Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine
title Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine
title_full Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine
title_fullStr Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine
title_full_unstemmed Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine
title_short Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine
title_sort case series of patients with coronavirus disease 2019 pneumonia treated with hydroxychloroquine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057902/
https://www.ncbi.nlm.nih.gov/pubmed/36984543
http://dx.doi.org/10.3390/medicina59030541
work_keys_str_mv AT tanakatomohiro caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine
AT okamotomasaki caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine
AT matsuonorikazu caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine
AT naitounishidayoshiko caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine
AT nounotakashi caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine
AT kojimatakashi caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine
AT nishiiyuuya caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine
AT uchiyashikiyoshihiro caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine
AT takeokahiroaki caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine
AT nagasakiyoji caseseriesofpatientswithcoronavirusdisease2019pneumoniatreatedwithhydroxychloroquine